Grace Therapeutics (GRCE) Total Liabilities (2017 - 2026)
Grace Therapeutics (GRCE) posted Total Liabilities of $2.8 million for Q1 2026, down 23.3% sequentially from $3.6 million in Q4 2025, and down 48.76% YoY from $5.4 million in Q1 2025.
Grace Therapeutics (GRCE) Total Liabilities (2017 - 2026) Analysis & Trends
Grace Therapeutics has reported Total Liabilities for 10 years, with the latest figure at $2.8 million in Q1 2026.
- Quarterly Total Liabilities fell 48.76% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (down 48.76% YoY) and the FY2026 annual result came in at $2.8 million, down 48.76% from the prior year.
- Total Liabilities declined to $2.8 million in Q1 2026 per GRCE's latest filing, from $3.6 million in the prior quarter.
- Over five years, Total Liabilities peaked at $20.7 million in Q3 2022 and troughed at $2.8 million in Q1 2026.
- A 5-year average of $11.0 million and a median of $10.4 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities jumped 534.47% in 2022, then plunged 60.42% in 2025.
- Over 5 years, Total Liabilities stood at $20.1 million in 2022, then slumped by 42.71% to $11.5 million in 2023, then slipped by 21.03% to $9.1 million in 2024, then slumped by 60.42% to $3.6 million in 2025, then dropped by 23.3% to $2.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $2.8 million, $3.6 million, and $3.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | 1.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.86 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 3.60 Mn |
| Sep 30, 2025 | 3.76 Mn |
| Jun 30, 2025 | 6.26 Mn |
| Mar 31, 2025 | 5.38 Mn |
| Dec 31, 2024 | 9.09 Mn |
| Sep 30, 2024 | 9.22 Mn |
| Jun 30, 2024 | 10.35 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Dec 31, 2023 | 11.51 Mn |
| Sep 30, 2023 | 11.47 Mn |
| Jun 30, 2023 | 9.02 Mn |
| Mar 31, 2023 | 11.17 Mn |
| Dec 31, 2022 | 20.08 Mn |
| Sep 30, 2022 | 20.75 Mn |
| Jun 30, 2022 | 20.53 Mn |
| Mar 31, 2022 | 20.35 Mn |
| Dec 31, 2021 | 3.17 Mn |
| Sep 30, 2021 | 5.59 Mn |